Delta Lloyd’s Teva Pharmaceuticals TEVA Stock Holding History

Delta Lloyd’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-107,281	Closed	-$3.89M	–	445
2016 Q4	$3.89M	Buy	107,281 +41,281	+63%	+$1.65M	0.12%	165
2016 Q3	$3.04M	Hold	66,000	–	–	0.09%	173
2016 Q2	$3.31M	Sell	66,000 -5,071	-7%	-$270K	0.11%	147
2016 Q1	$3.8M	Hold	71,071	–	–	0.13%	141
2015 Q4	$4.67M	Buy	71,071 +4,550	+7%	+$281K	0.16%	106
2015 Q3	$3.76M	Hold	66,521	–	–	0.12%	147
2015 Q2	$3.93M	Buy	66,521 +25,482	+62%	+$1.57M	0.12%	142
2015 Q1	$2.56M	Hold	41,039	–	–	0.08%	153
2014 Q4	$2.36M	Hold	41,039	–	–	0.07%	165
2014 Q3	$2.21M	Buy	41,039 +4,417	+12%	+$234K	0.02%	164
2014 Q2	$1.92M	Buy	36,622 +2,981	+9%	+$152K	0.06%	167
2014 Q1	$1.78M	Buy	33,641 +3,259	+11%	+$151K	0.06%	154
2013 Q4	$1.22M	Buy	30,382 +4,529	+18%	+$178K	0.04%	209
2013 Q3	$977K	Buy	25,853 +2,915	+13%	+$114K	0.04%	239
2013 Q2	$899K	Buy	+22,938	New	+$893K	0.03%	236

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Delta Lloyd's TEVA Position: Q1 2017 in Review

Delta Lloyd sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 107,281 shares — an estimated $3.89M sold.

Delta Lloyd first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $4.67M in Q4 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Delta Lloyd reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Delta Lloyd sold 107,281 Teva Pharmaceuticals shares in Q1 2017, an estimated $3.89M.
Delta Lloyd first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Delta Lloyd's Teva Pharmaceuticals position peaked at $4.67M in Q4 2015.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Delta Lloyd's 13F filing for Q1 2017, filed 10 May 2017.